These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 25330122

  • 1. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA, Snavely DB, Hargreaves RJ, Szegedi A, Lines C, Reines SA.
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial.
    Xiao L, Zhu X, Gillespie A, Feng Y, Zhou J, Chen X, Gao Y, Wang X, Ma X, Gao C, Xie Y, Pan X, Bai Y, Xu X, Wang G, Chen R.
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [Abstract] [Full Text] [Related]

  • 3. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
    Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S.
    Biol Psychiatry; 2006 Feb 01; 59(3):216-23. PubMed ID: 16248986
    [Abstract] [Full Text] [Related]

  • 4. Clinical experience with substance P receptor (NK1) antagonists in depression.
    Ranga K, Krishnan R.
    J Clin Psychiatry; 2002 Feb 01; 63 Suppl 11():25-9. PubMed ID: 12562140
    [Abstract] [Full Text] [Related]

  • 5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 01; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.
    J Clin Psychiatry; 2004 Oct 01; 65(10):1356-64. PubMed ID: 15491239
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials.
    Dunner DL, Lipschitz A, Pitts CD, Davies JT.
    Clin Ther; 2005 Dec 01; 27(12):1901-11. PubMed ID: 16507376
    [Abstract] [Full Text] [Related]

  • 8. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.
    Millan MJ, Dekeyne A, Gobert A, Mannoury la Cour C, Brocco M, Rivet JM, Di Cara B, Lejeune F, Cremers TI, Flik G, de Jong TR, Olivier B, de Nanteuil G.
    Eur Neuropsychopharmacol; 2010 Sep 01; 20(9):599-621. PubMed ID: 20483567
    [Abstract] [Full Text] [Related]

  • 9. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.
    J Clin Psychopharmacol; 2008 Dec 01; 28(6):631-7. PubMed ID: 19011431
    [Abstract] [Full Text] [Related]

  • 10. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM, Dellva MA, Waterman K, Greenbaum M, Poppe C, Goldberger C, Ahl J, Perahia DG.
    Curr Med Res Opin; 2015 Jun 01; 31(6):1179-89. PubMed ID: 25894953
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM, Gao KR, Yu H, Shen YF, Li HF.
    J Clin Psychopharmacol; 2018 Jun 01; 38(3):226-233. PubMed ID: 29620692
    [Abstract] [Full Text] [Related]

  • 12. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.
    Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G, Squassante L, Bye A, Trist D, Krishnan KR, Fernandes S.
    J Clin Psychopharmacol; 2011 Dec 01; 31(6):727-33. PubMed ID: 22020354
    [Abstract] [Full Text] [Related]

  • 13. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder.
    Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW.
    J Psychopharmacol; 2003 Sep 01; 17(3):276-82. PubMed ID: 14513919
    [Abstract] [Full Text] [Related]

  • 14. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ.
    Eur Psychiatry; 2006 Sep 01; 21(6):367-78. PubMed ID: 16697153
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.
    J Clin Psychiatry; 2006 Feb 01; 67(2):288-96. PubMed ID: 16566626
    [Abstract] [Full Text] [Related]

  • 16. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov 01; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 17. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
    Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y.
    Neuropsychopharmacology; 2004 Feb 01; 29(2):385-92. PubMed ID: 14666114
    [Abstract] [Full Text] [Related]

  • 18. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS, Cooper JA, Huusom AK, Hindmarch I.
    Int Clin Psychopharmacol; 2006 May 01; 21(3):159-69. PubMed ID: 16528138
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.
    Vieta E, Thase ME, Naber D, D'Souza B, Rancans E, Lepola U, Olausson B, Szamosi J, Wilson E, Hosford D, Dunbar G, Tummala R, Eriksson H.
    Eur Neuropsychopharmacol; 2014 Apr 01; 24(4):564-74. PubMed ID: 24507016
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea.
    Pae CU, Bahk WM, Jon DI, Lee SY, Yoon BH, Min KJ.
    Hum Psychopharmacol; 2007 Aug 01; 22(6):351-9. PubMed ID: 17487934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.